- Home
- » Tags
- » ALK inhibitor
Top View
- Oncology Presentation
- Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
- Emerging Therapies for Non-Small Cell Lung Cancer Chao Zhang1,3, Natasha B
- Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple
- Product Monograph
- Rozlytrek, INN-Entrectinib)
- Oncology Agents Policy #: Rx.01.67
- Focus on ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC)
- Management of Acquired Resistance to ALK Inhibitors: Repeat Biopsy to Characterize Mechanisms of Resistance Does Not Significantly Impact Clinical Outcomes
- Pivotal Data for Roche Medicines in Lung and Blood Cancers to Be
- PF-06463922 Is a Potent and Selective Next-Generation ROS1/ALK Inhibitor Capable of Blocking Crizotinib-Resistant ROS1 Mutations
- MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer a C Ibiayi Dagogo-Jack1,2, Satoshi Yoda1,2, Jochen K
- Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
- ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms Kasey L
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
- ENTRECTINIB BRIEFING DOCUMENT Meeting Date
- Head to Head Evaluation of Second Generation ALK Inhibitors Brigatinib
- Efficacy of Combination Treatment Using YHO-1701, an Orally Active
- Role and Targeting of Anaplastic Lymphoma Kinase in Cancer
- Brigatinib: New-Generation ALK Inhibitor for Nonsmall Cell Lung Cancer
- Targeting ALK-Positive Non-Small-Cell Lung Cancer–Novel Inhibitors
- Resistance Mechanisms to Targeted Therapies in ROS1 and ALK Non
- ALK) Inhibitors in the Treatment Of
- Exceptional Response to the ALK and ROS1 Inhibitor Lorlatinib and Subsequent Mechanism of Resistance in Relapsed ALK F1174L-Mutated Neuroblastoma
- Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): a Clinical and Preclinical Overview
- Repotrectinib (TPX-0005), Effectively Reduces Growth of ALK Driven
- Small Cell Lung Cancer – First Line
- Epithelial-To-Mesenchymal Transition Is a Mechanism of ALK Inhibitor
- Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
- Interactions of Alectinib with Human ABC Drug Efflux Transporters And
- New Target Therapies in Advanced Non-Small Cell Lung Cancer: a Review of the Literature and Future Perspectives